Switzerland : At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth - (MarketWatch via NewsPoints Desk)

  • At its annual Meet Novartis Management event, the Swiss drugmaker offered some insights into its strategy to focus the company and drive sustainable growth, reported MarketWatch.

  • CEO Vas Narasimhan said the company is "confident that our portfolio of novel medicines, together with our strategy to become a more focused medicines company, will result in sustainable top- and bottom-line growth."

  • For the innovative medicines pharmaceuticals unit, Novartis management highlighted Cosentyx and Entresto, as well as 10 potential blockbuster launches in the next three years, including Aimovig, BAF312 and RTH258.

  • Novartis also said its innovative medicines oncology division returned to growth with 6 percent higher sales in the first quarter, driven by Tafinlar plus Mekinist, Promacta and Jakavi. Also, three new launches, Kisqali, Kymriah and Lutathera, are expected to further drive growth in the mid-term.

  • In addition, the company said oncology is expected to have 15 major filings and 13 approvals in 2018 and sizable filing opportunities in 2019, including SEG101 and the combination of PDR001 with Tafinlar plus Mekinist.

  • Novartis also highlighted the sale of its "stake in the consumer healthcare [joint venture] to GlaxoSmithKline and (we) invested more in gene therapy and oncology," adding that "we are positioned to deliver sales growth and margin expansion through 2022."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.